Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Awakn Life Sciences Corp C.AWKN

Alternate Symbol(s):  AWKNF

Healthcare Psychedelics
Awakn Life Sciences Corp. is a Canada-based clinical-stage biotechnology company. The Company is developing therapeutics for substance use and mental health disorders, with a near-term focus on Alcohol Use Disorder (AUD). The Company's therapeutics are focused on the brain circuits that drive addiction, multiple receptors rather than the traditional single drug receptor targets. The Company... see more

Recent & Breaking News (CSE:AWKN)

Awakn Life Sciences Appoints UK Leader in Addictions Psychiatry, Dr. Arun Dhandayudham, as Chief Medical Officer

Newsfile May 17, 2022

Awakn Life Sciences to Participate in Upcoming May 2022 Conferences

Newsfile May 5, 2022

Awakn Life Sciences Reports Fiscal Fourth Quarter and Fiscal Year January 31, 2022, Results

Newsfile April 28, 2022

Awakn Life Sciences Provides Shareholder Update on Three Operational Ketamine-Assisted Therapy Clinics in the UK and Norway

Newsfile April 13, 2022

Awakn Successfully Completes Phase One of Its Drug Discovery Program

Newsfile April 6, 2022

Awakn Life Sciences to Participate in Upcoming April 2022 Conferences

Newsfile April 5, 2022

Awakn Life Sciences Announces Closing of Private Placement

Newsfile March 22, 2022

Canadian Ketamine Therapy Comes to London, UK

Stockhouse Editorial March 18, 2022

The StockTalk Cannabis Report: Mar 18, 2022

Dave Jackson March 18, 2022

Awakn Life Sciences Receives Regulatory Approval for Flagship Clinic in London to Begin Delivering Treatments

Newsfile March 17, 2022

Awakn Life Sciences Appoints Kevin Lorenz as U.S. Head of Commercial Development

Newsfile March 15, 2022

Awakn Life Sciences to Participate at Upcoming March 2022 Conferences

Newsfile March 9, 2022

NEO Biotech Stock Files Patent for Substance & Behavioral Addiction Treatment

Stockhouse Editorial February 18, 2022

Awakn Life Sciences Drug Discovery Program Files Patent Application for a New Class of Entactogen-Like Molecules

Newsfile February 17, 2022

Awakn Life Sciences' Professor Celia Morgan Named One of the Most Influential Women in the Psychedelics Industry

Newsfile February 15, 2022

Awakn Life Sciences to Host Fireside Chat with Dr. Ben Sessa, Chief Medical Officer, on March 2nd at 11:00am EST

Newsfile February 10, 2022

Awakn Life Sciences Files Patent Application for a New Class of Entactogen-Like Molecules to Treat a Broad Range of Addictions

Newsfile January 26, 2022

Awakn Life Sciences Signs MOU with Maps

Newsfile January 19, 2022

Awakn Responds to OTC Markets Request on Recent Promotional Activity

Newsfile January 14, 2022

Awakn Life Sciences Announces Positive Results from Phase II A/B Ketamine-Assisted Therapy for Treatment of Alcohol Use Disorder Trial

Newsfile January 11, 2022